Stuider om reumatoid artrit


Cross M et al
The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study
Ann Rheum Dis. 2014 Jul;73(7):1316-22

McInnes IB and Schett G
The pathogenesis of rheumatoid arthritis
N Engl J Med. 2011 Dec 8;365(23):2205-19

Braun J and Kay J
The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis
Expert Opin Drug Saf. 2017 Mar;16(3):289-302

Smolen JS et al
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Ann Rheum Dis. 2017 Jun;76(6):960-977

Burmester GR and Pope JE
Novel treatment strategies in rheumatoid arthritis
Lancet. 2017 Jun 10;389(10086):2338-2348


van Aken J et al
Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis
Ann Rheum Dis. 2004 Mar;63(3):274-9

Goekoop-Ruiterman YP et al
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial.
Arthritis Rheum. 2008 Feb;58(2 Suppl):S126-35

Hazlewood GS et al
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.
BMJ. 2016 Apr 21;353:i1777

Fleischmann R et al
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Lancet. 2017 Jul 29;390(10093):457-468

Maini R et al
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Lancet. 1999 Dec 4;354(9194):1932-9

Jørgensen KK et al
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Lancet. 2017 Jun 10;389(10086):2304-2316